ADL Amdl,

TUSTIN, Calif., May 10 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi and Jilin China, through its wholly owned subsidiary Jade Pharmaceutical Inc. (JPI), is an international biopharma company. AMDL, together with Jade, engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. AMDL announced today that Jade, through its subsidiary JJB, has signed a new Distribution and Agency Agreement with Double Crane Medicine Co. Ltd. (Changsha). This one-year renewable agreement covers the provinces and cities of Hunan, Hubei, Sichuan, Chongqing, Guangxi, Yunnan and Guizhou. Double Crane Medicine will initially be selling 12 various Jade products including Domperidon tablets, Ondansetron Injections, Chondroitin Sulfate Injections, GuYanLin Compounds, Benzoic Acid /Camphor Solutions, and Levofloxacin & Lactate Injections. Mr. Frank Zhang, Managing Director of JPI, stated that "the signing of this new distribution agreement with DCPC will position Jade to significantly ramp up sales in the Southern China region over the next 12 months. Domperidon tablets are expected to be the biggest selling product, as JPI's generic version of this product is anticipated to be significantly lower priced than competitors. Product pricing is always a key driver in most of China's markets." Mr. Gary Dreher, AMDL CEO, noted that "this new regional Chinese distribution relationship with DCPC is truly exciting and elevates JPI's status in the ever expanding Chinese pharma market. AMDL intends to deploy more capital to JPI in order to ensure that JPI can meet any demand for JPI's growing line of innovative pharma products." About Jade: Jade has access to the fastest growing pharmaceutical and consumer market in the world: China. Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice standards. About Double Crane Pharmaceutical Co., Ltd.: DCPC was jointly established in May 15th 1997 and successfully listed in 2002 on the Shanghai Stock Exchange and its general indexes ranked it in the top 500 Chinese enterprises. From 1997 to 2006, business revenue of DCPC rose from approximately (US) $29.1 million to (US) $455 million, with an annual increase of 73.3%; net profit rose from (US) $5.9 million to (US) $20.7 million, with an annual increase of 28.5%, Total assets rose from (US) $70.37 million to (US) $446 million, with an annual increase of 44.7%. Hunan Double Crane Pharmaceutical Company Ltd. is the largest subsidiary of Double Crane Pharmaceutical Co., Ltd. About AMDL AMDL, Inc., headquartered in Tustin, California, with operations in Shenzhen, Jaingxi and Jilin China through its wholly owned subsidiary Jade Pharmaceutical Inc., is an international biopharma company. AMDL together with Jade engages in the development, manufacture and marketing of proprietary pharmaceutical and testing products. More information about AMDL and its products can be obtained at http://www.amdl.com/. Forward-Looking Statements This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur. Contact: AMDL, Inc. Gary L. Dreher President & CEO (714) 505-4460 DATASOURCE: AMDL, Inc. CONTACT: Gary L. Dreher, President & CEO of AMDL, Inc., +1-714-505-4460 Web site: http://www.amdl.com/

Copyright